Health Discovery Corporation Appoints Maher Albitar M.D., Former Medical Director Of Hematology And Oncology And Chief Of Research And Development At Quest Diagnostics, Chief Medical Officer
Health Discovery Corporation (OTCBB: HDVY) (HDC) announced today the appointment of Maher Albitar, M.D., a world renowned cancer scientist and inventor, to the position of Chief Medical Officer. Until recently, Dr. Albitar was the Medical Director of Hematology and Oncology and Chief of Research and Development at Quest Diagnostics Nichols Institute (NYSE: DGX), San Juan Capistrano, Calif. Prior to Quest Diagnostics, Dr. Albitar was a tenured full professor at the M.D. Anderson Cancer Center and the University of Texas, where he served as chief of the hematopathology of the leukemia section with joint appointment in the clinical leukemia department.
“Dr. Albitar is a globally respected cancer researcher with the unique combination of both academic and commercial experience having held high level appointments at Quest Diagnostics, the largest commercial clinical laboratory in the world, as well as M.D. Anderson Cancer Center, voted the top hospital in the nation for cancer care, according to the U.S. News & World Report annual 'America's Best Hospitals,'” said Stephen D. Barnhill, M.D., Chairman and CEO at Health Discovery Corporation. “We’re thrilled to have Dr. Albitar join our team and lead our molecular diagnostic and medical imaging discovery, development and commercialization program.”
“For a long-time, I’ve admired Dr. Barnhill and his cutting-edge work in addressing the urgent need for effective cancer diagnostic test development,” said Dr. Albitar. “I am very impressed with HDC’s progress in prostate cancer, breast cancer, colon cancer, leukemia, pancreatic cancer and melanoma, and I am looking forward to working closely with the distinguished team at HDC to increase the pipeline of cancer diagnostic and prognostic tests and prepare these tests for commercialization.”
Dr. Albitar will immediately help position the Company to expand its pipeline of molecular diagnostic and medical imaging tests for cancer using the Company’s patented Support Vector Machine technology. The Company holds 43 issued patents and 32 pending patents related to its SVM and SVM-RFE development tools.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV